J. Buesa

Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study

M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis et al. · Journal of Clinical Oncology · 1999 · 565 citations

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Armando Santoro, T Türsz, Henning T. Mouridsen et al. · Journal of Clinical Oncology · 1995 · 526 citations

A randomised phase II study on neo-adjuvant chemotherapy for ‘high-risk’ adult soft-tissue sarcoma

E. Gortzak, Alberto Azzarelli, J. Buesa et al. · European Journal of Cancer · 2001 · 376 citations

Surgical Oncology, Malignant Disease, Medicine +7

Deletions Affecting Codons 557-558 of the <i>c</i>-<i>KIT</i> Gene Indicate a Poor Prognosis in Patients With Completely Resected Gastrointestinal Stromal Tumors: A Study by the Spanish Group for Sarcoma Research (GEIS)

Javier Martín‐Broto, Andrés Poveda, Antonio Llombart‐Bosch et al. · Journal of Clinical Oncology · 2005 · 350 citations · Full text

Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study

Xavier García del Muro, Antonio López–Pousa, Joan Maurel et al. · Journal of Clinical Oncology · 2011 · 293 citations